Survival Analysis in Breast Cancer Patients Treated with Targeted Therapies and Conventional Therapies in the US: A Comparative Real World Study
Author(s)
Shreosi Sanyal, PhD1, Satish Kumar, MBA2, Dishant Sukhija, MBA2, Arunima Sachdev, MA2, Abhimanyu Roy, MBA2, Vikash Kumar Verma, BS Pharma, MBA3, Ina Kukreja, MBA, PT2, Abhinav Nayyar, MBBS, MBA2, Marissa Seligman, BS Pharma3, Louis Brooks Jr, MA4, Rahul Goyal, BS Tech5, Atish Chhaburao Musle, MBA2.
1Optum, Hyderabad, India, 2Optum, Gurgaon, India, 3Optum, Boston, MA, USA, 4Optum, Bloomsbury, NJ, USA, 5Optum, Phoenix, AZ, USA.
1Optum, Hyderabad, India, 2Optum, Gurgaon, India, 3Optum, Boston, MA, USA, 4Optum, Bloomsbury, NJ, USA, 5Optum, Phoenix, AZ, USA.
Presentation Documents
OBJECTIVES: Breast cancer is a leading cause of cancer-related mortality, necessitating ongoing research into effective treatment options. Targeted therapies have revolutionized the management of breast cancer, with improved patient outcomes and prolonged lifespan. This study aims to perform a comparative survival analysis for breast cancer patients treated with targeted therapies and only standard therapies, to understand the relative effectiveness of targeted therapies over conventional treatments.
METHODS: A total of 91,752 breast cancer patients were identified (June 2016 to June 2021), using claims and electronic health records data from Optum® de-identified Market Clarity database. After applying continuous eligibility and exclusion criteria, patients who received targeted therapies and only standard therapies were evaluated in the variable follow-up period (until June 2024). Targeted therapies included trastuzumab and its biosimilars, immune checkpoint inhibitors, and hormonal therapies, while chemotherapy and radiotherapy were considered standard therapies. Mortality rates were examined, and survival analysis was performed for these two treatment groups.
RESULTS: Overall, mortality rates of 18% and 20% were observed for patients treated with targeted and only standard therapies, respectively. Considering advanced stage breast cancer patients with metastasis, the mortality rate was 10% for patients treated with targeted therapies and 16% for standard therapies. Based on Kaplan-Meier survival analysis, it was observed that the all-cause mortality rate in patients with only standard therapies was significantly higher compared to patients with targeted therapies at 2.5 years (9.9% vs. 3.7%; p<0.001).
CONCLUSIONS: This research highlights the importance of targeted therapies in breast cancer patients, especially at advanced stages of the disease. By using a comprehensive real-world dataset, this study provides valuable insights into the effectiveness of targeted therapies outside controlled clinical trial. Further analysis will be performed using cox proportional hazards model, for a more nuanced understanding of patient survival over time.
METHODS: A total of 91,752 breast cancer patients were identified (June 2016 to June 2021), using claims and electronic health records data from Optum® de-identified Market Clarity database. After applying continuous eligibility and exclusion criteria, patients who received targeted therapies and only standard therapies were evaluated in the variable follow-up period (until June 2024). Targeted therapies included trastuzumab and its biosimilars, immune checkpoint inhibitors, and hormonal therapies, while chemotherapy and radiotherapy were considered standard therapies. Mortality rates were examined, and survival analysis was performed for these two treatment groups.
RESULTS: Overall, mortality rates of 18% and 20% were observed for patients treated with targeted and only standard therapies, respectively. Considering advanced stage breast cancer patients with metastasis, the mortality rate was 10% for patients treated with targeted therapies and 16% for standard therapies. Based on Kaplan-Meier survival analysis, it was observed that the all-cause mortality rate in patients with only standard therapies was significantly higher compared to patients with targeted therapies at 2.5 years (9.9% vs. 3.7%; p<0.001).
CONCLUSIONS: This research highlights the importance of targeted therapies in breast cancer patients, especially at advanced stages of the disease. By using a comprehensive real-world dataset, this study provides valuable insights into the effectiveness of targeted therapies outside controlled clinical trial. Further analysis will be performed using cox proportional hazards model, for a more nuanced understanding of patient survival over time.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PT2
Topic
Methodological & Statistical Research
Topic Subcategory
Artificial Intelligence, Machine Learning, Predictive Analytics
Disease
SDC: Oncology